Press Releases Johnson & Johnson Kazakhstan S.E.

Equities

JNJ_KZ

US4781601046

Real-time Estimate Cboe BZX Other stock markets 02:08:11 04/06/2024 am IST			5-day change	1st Jan Change
148.3 ^USD	+1.02%		-1.46%	-6.74%

12:44pm	J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO	RE
12:15pm	J&J-backed Rapport Therapeutics seeks to raise $144 mln in US IPO	RE

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Johnson & Johnson Completes Acquisition of Shockwave Medical	08:57pm	AQ
Johnson & Johnson - First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration	08:57pm	AQ
Johnson & Johnson Executive Vice President, William N. Hait, M.D., Ph.D., to Retire, Effective September 2024	31/05	AQ
Johnson & Johnson Completes Acquisition of Shockwave Medical	31/05	BU
Johnson & Johnson : to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) Press Release	30/05	PU
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results	29/05	AQ
Johnson & Johnson : to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) Transcript	29/05	PU
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis	28/05	AQ
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis	28/05	BU
Johnson & Johnson: Meet a nurse who leads clinical trials to find innovative cancer therapies	24/05	AQ
Johnson & Johnson : advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA	24/05	PU
Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation	22/05	BU
Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences	22/05	AQ
TREMFYA (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission	21/05	AQ
Novel biologic could offer ulcerative colitis symptomatic remission	21/05	AQ
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation	21/05	AQ
Johnson & Johnson : to Participate in the 2024 RBC Capital Markets Global Healthcare Conference Transcript	18/05	PU
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment	16/05	BU
Johnson & Johnson : to Participate in the BofA Securities Health Care Conference Transcript	15/05	PU
Johnson & Johnson : to Participate in the 2024 RBC Capital Markets Global Healthcare Conference Press Release	15/05	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 11:00 pm IST